Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mesoblast, Inc.
Cardiovascular disease is the single largest killer of males and females in the United States with an average of 335,000 deaths per year. This year an estimated 700,000 Americans will suffer an acute myocardial infarction. The standard of care treatment for acute myocardial infarction (MI) usually includes immediate perfusion, optimal pain relief, oxygen, aspirin or other anti-coagulants, Beta-Blockers, nitrates and Ace-inhibitors. Management of cardiac risk factors such as tobacco use, hypertension, lipid levels, diabetes, weight control and exercise all work to reduce further atherosclerotic events. Yet, many patients go on to develop Congestive Heart Failure (CHF). Medical management for CHF may improve symptoms and slow the progression to failure but does not restore a functioning myocardium. A therapy that could improve the myocardial remodeling process and reduce the incidence or severity of CHF following acute MI would provide a significant benefit in an area of unmet medical need.
Patients will receive standard of care in addition to stem cells or placebo.
Age
21–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female between 21 and 85 years old
First heart attack within 1 to 10 days
You may not be if
Positive for HIV 1 and 2
Previous heart attack
Pacemaker or other device
Pregnant or breastfeeding
Allergic to cow or pig derived products
Previous bone marrow transplant
Involved in another clinical trial within the past 30 days
Alcohol or recreational drug abuse within the past 6 months
Hepatitis Positive
Major surgical procedure or major trauma within the past 14 days
Body weight greater than 300 pounds
Autoimmune disease ( e.g. Lupus, Multiple Sclerosis)